RHOA and prostate cancer: While RhoA activation induces tail release [26] and more rounded cell morphology, the inhibition of its downstream effector ROCK by Y-27632 is associated with an elongated morphology in PC3 human prostatic cancer cells [27], NIH 3T3 fibroblasts [28], and podocytes [29].